Thank you for your queries in to the treatment Rytary (US)/ Patrome (EU). We did contact the European Medicines Agency (EMA) late last year to determine the situation regarding this treatment.
The EMA informed us that they had completed an evaluation of this levodopa/ carbidopa treatment developed by IMPAX laboratories, and recommended that it be authorised for use in the European Union. The EMA recommendation will now be forwarded on to the European Commission, the body with the authority to grant marketing authorisation of medicines in the EU.
However, it is important to note that once a medicine has received a marketing authorisation in the EU, it is up to the company (IMPAX) to decide when and in which countries in the EU they will market the medicine.
We will make sure to update you on any further information we receive about this treatment.
I hope this helps.